Flerie invests in and builds companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. They aim to differentiate themselves by using their network, expertise, and resources to achieve long-term success for their companies. Flerie emphasizes respect for all stakeholders and strives to be described as a great partner. Their investment strategy is evergreen, focusing on addressing unmet medical needs and tackling global healthcare challenges. The firm was established in 2011 by Thomas Eldered, co-founder of Recipharm. Building on Recipharm’s success, Flerie's strategy involves active participation in their portfolio companies, leveraging operational experience and a broad network of experts. They actively syndicate with investors from Europe, North America, the Middle East, and Asia. Flerie’s investment approach is centered around building product development and commercial growth companies operating primarily in drug development and related device and service spaces. The company's current portfolio includes diverse fields like immuno-oncology, metabolic diseases, biologics development and manufacturing, and even a cleantech company. The company listed on Nasdaq Stockholm in June 2024, strengthening its position and raising capital for continued growth. They are focused on advancing portfolio company pipelines to positively impact health and well-being.
Preferred startup development maturity for initial funding deployment.
Pharmaceutical, Biotech, Drug Development, Immuno-oncology, Metabolic Diseases, Biologics Development and Manufacturing, Cleantech, Medical Devices, Related Services
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...